| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 3281998 | Clinical Gastroenterology and Hepatology | 2014 | 8 Pages |
Abstract
In a phase 2 study, administration of allogeneic MSCs reduced CDAI and CDEIS scores in patients with luminal CD refractory to biologic therapy. ClinicalTrials.gov number, NCT01090817.
Keywords
GvHDIBDQCDEISMSCCDAIAQoLinflammationGraft-versus-host diseaseCrohn's diseaseAutoimmuneCellular therapyIntestineMesenchymal stromal cellcytomegalovirusCMVCrohn's Disease Activity IndexCrohn's Disease Endoscopic Index of SeverityImmune responseInflammatory Bowel Disease QuestionnaireC-reactive proteinCRP
Related Topics
Health Sciences
Medicine and Dentistry
Gastroenterology
Authors
Geoffrey M. Forbes, Marian J. Sturm, Rupert W. Leong, Miles P. Sparrow, Dev Segarajasingam, Adrian G. Cummins, Michael Phillips, Richard P. Herrmann,